Human epidermal growth factor receptor type 3 (HER3) plays a crucial role in the progression of many cancer types. In vivo radionuclide imaging could be a reliable method for repetitive detection of HER3-expression in tumors. The main challenge of HER3-imaging is the low expression in tumors together with endogenous receptor expression in normal tissues, particularly the liver. A HER3-targeting affibody molecule labeled with radiocobalt via a NOTA chelator [ 57 Co]Co-NOTA-Z 08699 has demonstrated the most favorable biodistribution profile with the lowest unspecific hepatic uptake and high activity uptake in tumors. We hypothesized that specific uptake of labeled affibody monomer might be selectively blocked in the liver but not in tumors by a co-injection of non-labeled corresponding trivalent affibody (Z 08699 ) 3 3 decreased with increasing monomer:trimer molar ratio. The tumor activity uptake and tumor-to-liver ratios were the highest for the 1:3 ratio. SPECT/CT images confirmed the biodistribution data. Imaging of HER3 expression can be improved by co-injection of a radiolabeled monomeric affibody-based imaging probe together with a trivalent affibody.
domain of HER3 is inactive, but the receptor can form active heterodimers with other members of the ErbB receptor family. One of the most potent heterodimers in tumorigenesis is the HER2/HER3 pair which activates downstream signaling pathways, e.g. PI-3K/Akt and MAPK/MEK4 2, 5 . Although clinically approved antibody-based drugs against HER2 expressing breast cancer, trastuzumab (Herceptin) and pertuzumab (Perjeta), have shown to be effective, many researchers have reported resistance against therapy by upregulation of other receptors in the ErbB receptor family, particularly HER3 6, 7 . The role of HER3-induced signaling in various tumors demonstrates its importance as a molecular target for therapy. Several monoclonal antibodies targeting HER3 are currently evaluated in the clinic 8, 9 . Molecular detection of HER3 expression for stratifying cancer patients who would respond to anti-HER3 treatment could be very beneficial. Currently, the predominant method for molecular profiling of tumors is biopsy. However, some issues are associated with this procedure, such as heterogeneous target expression in tumors and the invasiveness. Additionally, HER3 expression might change in response to applied therapy, meaning that the biopsy samples taken from the primary tumor will not be informative for metastases 10 . Radionuclide molecular imaging could help to overcome difficulties associated with the receptor expression heterogeneity and invasiveness. This would enable monitoring of receptor expression changes during treatment. The overexpression of HER3 in tumors is usually low, below 50,000 receptors/cell 11 . There is also endogenous expression of the protein in several organs, particularly the liver, which complicates imaging interpretation 11 . Therefore, imaging of HER3 expression is challenging and requires a probe with high affinity to HER3 (to increase uptake in lesions), rapid blood clearance and minimum uptake in healthy organs (to decrease background signal).
Affibody molecules are small (7 kDa) high-affinity scaffold proteins, which have demonstrated their targeting ability to several cancer-related receptors (e.g. EGFR, HER2 and IGF-1R) as well as their high potential as imaging agents 12 . Clinical studies using HER2-targeting affibody molecules have demonstrated their safety, specific targeting and high-contrast imaging 13, 14 . Affibody molecules binding to HER3 with low picomolar affinity have recently been generated and described in several studies [15] [16] [17] [18] [19] [20] [21] . A HER3-targeting affibody molecule was also tested in a pre-clinical therapy study with multiple injections without any detected toxicity 22, 23 . Different variants of the HER3-targeting affibody molecule were labeled with radioisotopes suitable for both single photon emission computed tomography (SPECT) and positron emission tomography (PET) 17, 18, 20, 21 . It was also demonstrated that anti-HER3 affibody molecules could be used to monitor changes of the HER3-expression 18 . Importantly, HER3-targeting affibody molecules have similar affinities to HER3 and its murine counterpart, mErbB3, which makes mice a realistic model for targeting evaluation 23, 24 . Recently, we demonstrated that a radiocobalt labeled anti-HER3 affibody molecule had the most favorable biodistribution profile (among previously tested variants) with the lowest unspecific hepatic uptake accompanied by high and stable uptake in tumors 19 . We were interested in radiocobalt because 55 Co (T 1/2 = 17.5 h, 76% β + ) enables PET imaging up to 24 h after injection. Cobalt-55 can be produced by cyclotrons and could therefore be available in the majority of PET facilities. We have also demonstrated that by optimization of the protein injected dose, activity uptake in liver but not in tumor could be suppressed 18 . Available data indicate that the hepatic uptake of anti-HER3 affibody molecules depends on two mechanisms, where one is HER3-mediated and the second is caused by unspecific interaction of the protein with hepatocytes [16] [17] [18] [19] . For other affibody molecules (targeting HER1 and HER2), it was found that monomeric constructs had significantly higher tumor uptake than corresponding dimeric constructs 25, 26 , most likely due to better extravasation 27 . Therefore, we hypothesized that the HER3-mediated hepatic uptake could be, to some extent, selectively saturated if a multimeric, non-labeled HER3-targeting affibody molecule would be co-injected with its radiolabeled monomeric form. A HER3-targeting trivalent affibody consisting of three linked anti-HER3 affibody molecules (Z 08699 ) 3 (~21 kDa) was thus generated.
In this study we investigated the influence of co-injection of the non-labeled trivalent anti-HER3 affibody molecule on biodistribution and tumor targeting of radiocobalt-labeled monomer ( 
Results
(Z 08699 ) 3 characterization. Analysis of the DOTA-conjugated (DOTA-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and purified trivalent affibody using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) showed pure recombinant protein of correct size (Fig. 1a) . The molecular mass for DOTA-(Z 08699 ) 3 was determined to be 22375 Da, which is in perfect agreement with the calculated mass (22375 Da) (Fig. 1b) . Circular dichroism spectroscopy during variable temperature measurement (VTM) demonstrated a melting temperature of 65 °C and excellent refolding capabilities of the construct (Fig. 1c) . Analytical RP-HPLC measured using 220 nm absorbance demonstrated a 96% purity for DOTA-conjugated (Z 08699 ) 3 with retention time of 16.7 minutes (Fig. 1d) . The kinetics of the binding reaction of DOTA-(Z 08699 ) 3 to recombinant HER3-mFc and mouse ErbB3 was determined using multi-cycle kinetics on a Biacore T200. For HER3, the association rate constant (k a ) was 4.7 ± 0. (Fig. 1e) . The affinity of NOTA-Z 08699 was included for comparison. For HER3, k a was 3.9 ± 2.8 × www.nature.com/scientificreports www.nature.com/scientificreports/ 500-fold molar excess of EDTA (ethylenediaminetetraacetic acid). Pre-saturation of receptors with non-labeled trivalent affibody demonstrated a significant decrease (p < 0.05) of the cell-associated activity when tested on HER3-expressing cells (Fig. 2a) , confirming specificity of the trivalent affibody to HER3-receptors. The assay on cellular processing performed with BxPC-3 cells demonstrated a rapid binding and constant increase of cellular uptake of activity and internalized fraction over time (Fig. 2b) . The internalized fraction reached 60% of total cell-associated activity at the 24 h time point, and the total cell-bound activity increased by 2-fold from 1 to 24 h during continuous incubation.
In vivo studies using BxPC-3 tumor bearing mice. Direct 3 (1.5 µg) in tumor bearing mice is presented in Table 1 . Radiolabeled trivalent affibody had significantly lower activity concentration in blood than radiolabeled monomer. Uptake in almost all studied normal organs and tissues was significantly higher for the trivalent affibody, except lungs (where it was equal to monomer) and kidneys (where monomer had significantly higher uptake). The most prominent was the difference in livers where uptake of trivalent affibody was 10-fold higher. However, tumor uptake was the same for monomer and trivalent affibody.
Additionally, biodistribution of [ 57 Co]Co-NOTA-Z 08699 (fixed labeled protein mass of 0.5 µg/animal) co-injected with unlabeled trivalent affibody DOTA-(Z 8699 ) 3 at monomer:trimer molar ratios of 1:0, 1:3 and 1:6 was studied 4 h post injection (pi) in BxPC-3 xenografted mice ( Table 2 ). The activity concentration in blood after injection of 0.5 µg of monomer was significantly higher than for monomer co-injected with trivalent affibody for 1:1 and 1:6 ratios. The lowest concentration was found for a monomer:trimer molar ratio of 1:6. Generally, uptake www.nature.com/scientificreports www.nature.com/scientificreports/ in normal organs decreased with increased molar ratio. Hepatic activity uptake for sole monomer was significantly higher than for other tested combinations. Among the tested ratios, significantly lower hepatic uptake was found for ratio 1:6. However, tumor activity uptake was the highest for 1:3 ratio. The maximum tumor-to-liver ratio was found at 1:3 monomer:trimer ratio, 1.0 ± 0.1, which was significantly higher than for 1:0, 1:1 and 1:6 molar ratios (Fig. 3) .
The biodistribution of [ ). Data for this experiment are presented in Table 3 and Fig. 4 3 (1:3) demonstrated that tumor activity uptake was significantly higher in the case of co-injection of trivalent affibody. Other tested organs and tissue did not differ significantly in activity uptake (except spleen that had lower activity uptake in the group that was co-injected with trivalent affibody). Tumor-to-organ ratios were significantly higher (except tumor-to-small intestine) for the group that was co-injected with trivalent affibody (Fig. 4) . Tumor-to-liver ratio increased with time and was 2.3 ± 0.5 24 h pi. Gastrointestinal tract** 3.3 ± 0.9 2.6 ± 0.3 1.7 ± 0.2 1.5 ± 0.6 Carcass** 5.4 ± 0.9 6.8 ± 0.6 6 ± 4 4 ± 3 3 4 h after being co-injected with different molar ratios in BxPC-3 tumor bearing mice. Data were assessed by one-way ANOVA with Bonferroni correction for multiple comparisons in order to determine significant differences (p < 0.05): a value for 1:0 ratio was significantly higher than for 1:1 ratio; b value for 1:0 ratio was significantly higher than for 1:3 ratio; c value for 1:0 ratio was significantly higher than for 1:6 ratio; d value for 1:1 ratio was significantly higher than for 1:3 ratio; e value for 1:1 ratio was significantly higher than for 1:6 ratio; f value for 1:3 ratio was significantly higher than for 1:6 ratio. The organ uptake values are expressed as a percentage of injected dose per gram of tissue weight (% ID/g). *Data for 1:1 ratio are from Table 1 3 (molar ratio 1:3). However, liver activity uptake was appreciably lower after co-injection with trivalent affibody.
Discussion
Endogenous expression of a molecular target in healthy tissue may be an issue in imaging procedures. The target-specific uptake of imaging probes in normal organs reduces contrast of tumor imaging. This problem is relatively easy to solve when target expression in normal tissue is appreciably lower than in tumors. It has been demonstrated for somatostatin analogues 28 , scaffold proteins (affibody molecules 14 ), and monoclonal antibodies (trastuzumab 29 ) that the use of an optimal injected protein dose may saturate target receptors in normal tissues but not in tumors and improve the imaging contrast. However, HER3 is a challenging target due to relatively low expression in tumors, and more sophisticated approaches are hence required. The aim of this project was to test the hypothesis whether or not the imaging contrast of HER3 expression using affibody molecules can be improved by a combination of an optimal molecular design of the tracer (combination of NOTA and radiocobalt as a label 19 ) and preferable saturation of HER3/mErbB3 in liver by co-injection of a multimeric HER3-specific www.nature.com/scientificreports www.nature.com/scientificreports/ affibody molecule. It was expected that the bulky trivalent affibody would have lower extravasation and tumor penetration rate compared with smaller monomer, which should prevent target saturation in tumors. The use of dimeric form of single-domain antibodies (sdAbs, nanobody, 12-15 kDa) for selective saturation of targets in the liver but not in tumor resulted in appreciably higher contrast in imaging of tumor-associated macrophages 30 . A different approach that could be of great interest to investigate further in preclinical models is the possibility to saturate the hepatic uptake by first injecting unlabeled monomeric HER3-targeting affibody molecule. Following this saturation, a second injection with radiolabeled monomer could be done and the tumor uptake could be further increased, leading to higher feasibility for future clinical imaging.
Slower dissociation of a trivalent affibody might be important for preferable binding to receptors in liver, where well-fenestrated vasculature would provide similar access for both monomer and trivalent affibody to receptor-expressing hepatocytes. One could expect slower dissociation due to avidity effect similar to anti-HER1 and anti-HER2 affibody molecules 31, 32 or anti-CD206 and anti-CD20 sdAbs 30, 33 . Indeed, the dissociation rate of the trivalent affibody was three-fold slower than for the monomer.
A DOTA chelator was incorporated into (Z 08699 ) 3 to permit radiolabeling and simplify cellular processing and biodistribution studies. Indium-111 was chosen as a label for DOTA-(Z 08699 ) 3 in the dual-label animal studies for comparison with [
57 Co]Co-NOTA-Z 08699 . This strategy allows for simultaneous analysis of the distribution for both probes in the same animals. The binding specificity of DOTA-(Z 08699 ) 3 to HER3-expressing cells in vitro was preserved after labeling with indium-111 (Fig. 2a) . The cellular processing of radiolabeled trivalent affibody demonstrated an internalization pattern similar to anti-HER3 monomer 16 , i.e. relatively rapid internalization (50% at 4 h) (Fig. 2b) . The in vitro characterization of radiolabeled trivalent affibody was performed to corroborate that its targeting and biological properties (target specificity and internalisation pattern) were preserved after labeling that allowed us to perform dual isotope study in vivo. However, internalization of HER3/mErbB3 in liver after binding of DOTA-(Z 08699 ) 3 should be favorable for preventing hepatic uptake of radiolabeled monomer.
The 1 ) that the trimeric construct had significantly higher uptake in mErbB3-expressing organs, such as salivary gland, liver, spleen and small intestines. At the same time, activity concentration in blood was significantly lower for trivalent affibody than for the monomer that could be explained by sequestering of the conjugate by normal organs. This experiment confirmed that hepatic uptake of the trivalent affibody is by one order of magnitude higher than the hepatic uptake of the monomer. Further experiments ( Table 2 , Fig. 3 ) demonstrated that co-injection of DOTA-(Z 08699 ) 3 and [
57 Co]Co-NOTA-Z 08699 at a 1:3 molar ratio provided the best tumor-to-liver ratio for the radiolabeled affibody molecule. Obviously, re-optimization would be required for clinical application. A previous study has demonstrated that tumor-to-liver ratio increased with time because retention of activity was better in the tumor in comparison to the liver 19 . Blocking hepatic uptake with DOTA-(Z 08699 ) 3 resulted in a tumor-to-liver ratio of 2.3 ± 0.5 at 24 h pi, which is the best value for HER3-targeting affibody molecules obtained in preclinical studies. We would like to point out that the increased tumor-to-liver ratio is a qualitative, rather than quantitative change, providing us with an improved imaging contrast. A higher tumor-to-liver ratio for co-injection of DOTA-(Z 08699 ) 3 could also be observed in microSPECT images (Fig. 5 ). In combination with 18 F-FDG PET for initial lesion detection, this should enable visualization of HER3 expression in hepatic metastases, which are common in many types of cancer. Other tumor-to-organ ratios were also significantly higher at 24 h with the co-injection of the trimer compared to the optimal injected protein dose of the monomer (Fig. 4) . The use of 55 Co as a label would enable imaging 24 h after injection. www.nature.com/scientificreports www.nature.com/scientificreports/ In conclusion, imaging of HER3 expression in tumors can be improved by co-injection of a radiolabeled monomeric affibody-based imaging probe together with an trivalent affibody.
Material and Methods
Materials. The cell line BxPC-3 (pancreatic carcinoma) used during in vitro and in vivo experiments was purchased from American Type Tissue Culture Collection (ATCC via LGC Promochem, Borås, Sweden). Production and characterization of the monomeric affibody molecule NOTA-Z 08699 was previously published 17 . The activity content in samples was measured using automated gamma-counter with 3-inch NaI(Tl) detector (1480 WIZARD, Wallac Oy). Data were assessed by an unpaired, two-tailed t-test or by one-way ANOVA with Bonferroni correction for multiple comparisons using GraphPad Prism (version 6 for Windows GraphPad Software) in order to determine significant differences (p < 0.05). Obtained values are presented as average with standard deviation if not stated otherwise.
Construction and production of (Z 08699 ) 3 . Trimeric affibody molecule containing three monomeric Z 08699 affibody molecules interlinked by a VE-linker capped by an N-terminal HE-tag and a unique C-terminal cysteine was constructed using conventional restriction enzyme cloning. The trimeric affibody is denoted (Z 08699 ) 3 . The construct was cloned into pET26b+ vector (Novagen) and Sanger sequencing was used to confirm the correct insert. The construct was transformed into E. coli BL-21 (DE3) and produced by growing bacteria in tryptic soy broth containing kanamycin. Protein production was induced when OD 600nm reached 0.5 by addition of 1 mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG), and the culture was incubated at 25 °C overnight. Bacteria were lysed using Aminco french press (Laurier Research Instrumentation).
